PubRank

Darell D Bigner

Author PubWeight™ 454.67‹?›

Top papers

Rank Title Journal Year PubWeight™‹?›
1 Mutations of the BRAF gene in human cancer. Nature 2002 65.42
2 An integrated genomic analysis of human glioblastoma multiforme. Science 2008 51.36
3 IDH1 and IDH2 mutations in gliomas. N Engl J Med 2009 32.41
4 Glioma stem cells promote radioresistance by preferential activation of the DNA damage response. Nature 2006 27.91
5 Bevacizumab plus irinotecan in recurrent glioblastoma multiforme. J Clin Oncol 2007 12.62
6 The somatic genomic landscape of glioblastoma. Cell 2013 11.73
7 Phase II trial of bevacizumab and irinotecan in recurrent malignant glioma. Clin Cancer Res 2007 9.21
8 The genetic landscape of the childhood cancer medulloblastoma. Science 2010 8.34
9 TERT promoter mutations occur frequently in gliomas and a subset of tumors derived from cells with low rates of self-renewal. Proc Natl Acad Sci U S A 2013 6.88
10 Stem cell-like glioma cells promote tumor angiogenesis through vascular endothelial growth factor. Cancer Res 2006 6.77
11 Immunologic escape after prolonged progression-free survival with epidermal growth factor receptor variant III peptide vaccination in patients with newly diagnosed glioblastoma. J Clin Oncol 2010 6.30
12 Comprehensive, Integrative Genomic Analysis of Diffuse Lower-Grade Gliomas. N Engl J Med 2015 5.71
13 Altered telomeres in tumors with ATRX and DAXX mutations. Science 2011 4.60
14 Mutations of PIK3CA in anaplastic oligodendrogliomas, high-grade astrocytomas, and medulloblastomas. Cancer Res 2004 4.26
15 Subgroup-specific structural variation across 1,000 medulloblastoma genomes. Nature 2012 4.13
16 Protein typing of circulating microvesicles allows real-time monitoring of glioblastoma therapy. Nat Med 2012 4.11
17 Frequent ATRX, CIC, FUBP1 and IDH1 mutations refine the classification of malignant gliomas. Oncotarget 2012 3.88
18 Phase II trial of gefitinib in recurrent glioblastoma. J Clin Oncol 2003 3.83
19 Profiling the effects of isocitrate dehydrogenase 1 and 2 mutations on the cellular metabolome. Proc Natl Acad Sci U S A 2011 3.66
20 Mutant epidermal growth factor receptor (EGFRvIII) contributes to head and neck cancer growth and resistance to EGFR targeting. Clin Cancer Res 2006 3.28
21 Increased regulatory T-cell fraction amidst a diminished CD4 compartment explains cellular immune defects in patients with malignant glioma. Cancer Res 2006 3.02
22 Glioblastoma multiforme: a review of where we have been and where we are going. Expert Opin Investig Drugs 2009 2.90
23 The integrated landscape of driver genomic alterations in glioblastoma. Nat Genet 2013 2.89
24 Gene expression profiling and genetic markers in glioblastoma survival. Cancer Res 2005 2.63
25 Recent advances in the treatment of malignant astrocytoma. J Clin Oncol 2006 2.55
26 Identification of OTX2 as a medulloblastoma oncogene whose product can be targeted by all-trans retinoic acid. Cancer Res 2005 2.35
27 Phase II trial of temozolomide in patients with progressive low-grade glioma. J Clin Oncol 2003 2.16
28 Proteomic and immunologic analyses of brain tumor exosomes. FASEB J 2008 2.11
29 2-hydroxyglutarate production, but not dominant negative function, is conferred by glioma-derived NADP-dependent isocitrate dehydrogenase mutations. PLoS One 2011 2.00
30 Greater chemotherapy-induced lymphopenia enhances tumor-specific immune responses that eliminate EGFRvIII-expressing tumor cells in patients with glioblastoma. Neuro Oncol 2010 1.99
31 Epidermal growth factor receptor VIII peptide vaccination is efficacious against established intracerebral tumors. Clin Cancer Res 2003 1.92
32 Integrated genomic analyses identify ERRFI1 and TACC3 as glioblastoma-targeted genes. Oncotarget 2010 1.88
33 Systemic CTLA-4 blockade ameliorates glioma-induced changes to the CD4+ T cell compartment without affecting regulatory T-cell function. Clin Cancer Res 2007 1.86
34 Efficacy of intracerebral microinfusion of trastuzumab in an athymic rat model of intracerebral metastatic breast cancer. Clin Cancer Res 2003 1.85
35 OTX2 is critical for the maintenance and progression of Shh-independent medulloblastomas. Cancer Res 2009 1.77
36 Intracerebral infusate distribution by convection-enhanced delivery in humans with malignant gliomas: descriptive effects of target anatomy and catheter positioning. Neurosurgery 2007 1.74
37 A novel low-molecular weight inhibitor of focal adhesion kinase, TAE226, inhibits glioma growth. Mol Carcinog 2007 1.74
38 Development of novel targeted therapies in the treatment of malignant glioma. Nat Rev Drug Discov 2004 1.74
39 An epidermal growth factor receptor variant III-targeted vaccine is safe and immunogenic in patients with glioblastoma multiforme. Mol Cancer Ther 2009 1.67
40 Combination therapy of inhibitors of epidermal growth factor receptor/vascular endothelial growth factor receptor 2 (AEE788) and the mammalian target of rapamycin (RAD001) offers improved glioblastoma tumor growth inhibition. Mol Cancer Ther 2005 1.66
41 Mutant metabolic enzymes are at the origin of gliomas. Cancer Res 2009 1.66
42 Medical diagnostic radiation exposures and risk of gliomas. Radiat Res 2011 1.64
43 The addition of bevacizumab to standard radiation therapy and temozolomide followed by bevacizumab, temozolomide, and irinotecan for newly diagnosed glioblastoma. Clin Cancer Res 2011 1.64
44 Phase I trial of temozolomide plus O6-benzylguanine for patients with recurrent or progressive malignant glioma. J Clin Oncol 2005 1.63
45 Progress report of a Phase I study of the intracerebral microinfusion of a recombinant chimeric protein composed of transforming growth factor (TGF)-alpha and a mutated form of the Pseudomonas exotoxin termed PE-38 (TP-38) for the treatment of malignant brain tumors. J Neurooncol 2003 1.63
46 Phase 1 trial of gefitinib plus sirolimus in adults with recurrent malignant glioma. Clin Cancer Res 2006 1.63
47 A heterozygous IDH1R132H/WT mutation induces genome-wide alterations in DNA methylation. Genome Res 2012 1.63
48 Systemic anti-CD25 monoclonal antibody administration safely enhances immunity in murine glioma without eliminating regulatory T cells. Clin Cancer Res 2006 1.62
49 Intracerebral infusion of an EGFR-targeted toxin in recurrent malignant brain tumors. Neuro Oncol 2008 1.59
50 Clinical experience with alpha-particle emitting 211At: treatment of recurrent brain tumor patients with 211At-labeled chimeric antitenascin monoclonal antibody 81C6. J Nucl Med 2007 1.57
51 Monoclonal antibody blockade of IL-2 receptor α during lymphopenia selectively depletes regulatory T cells in mice and humans. Blood 2011 1.54
52 Phase II trial of temozolomide plus o6-benzylguanine in adults with recurrent, temozolomide-resistant malignant glioma. J Clin Oncol 2009 1.53
53 Bone-related genes expressed in advanced malignancies induce invasion and metastasis in a genetically defined human cancer model. J Biol Chem 2003 1.52
54 Phase II trial of carmustine plus O(6)-benzylguanine for patients with nitrosourea-resistant recurrent or progressive malignant glioma. J Clin Oncol 2002 1.50
55 Tumor-specific immunotherapy targeting the EGFRvIII mutation in patients with malignant glioma. Semin Immunol 2008 1.47
56 Disruption of wild-type IDH1 suppresses D-2-hydroxyglutarate production in IDH1-mutated gliomas. Cancer Res 2012 1.46
57 Bispecific antibodies engage T cells for antitumor immunotherapy. Expert Opin Biol Ther 2011 1.45
58 Systemic administration of a bispecific antibody targeting EGFRvIII successfully treats intracerebral glioma. Proc Natl Acad Sci U S A 2012 1.44
59 Glycoprotein nonmetastatic melanoma protein B, a potential molecular therapeutic target in patients with glioblastoma multiforme. Clin Cancer Res 2006 1.41
60 Mutations in IDH1, IDH2, and in the TERT promoter define clinically distinct subgroups of adult malignant gliomas. Oncotarget 2014 1.40
61 EGFRvIII-targeted vaccination therapy of malignant glioma. Brain Pathol 2009 1.40
62 Clinical utility of a patient-specific algorithm for simulating intracerebral drug infusions. Neuro Oncol 2007 1.39
63 Glioblastoma multiforme: a review of therapeutic targets. Expert Opin Ther Targets 2009 1.38
64 Immunological responses in a patient with glioblastoma multiforme treated with sequential courses of temozolomide and immunotherapy: case study. Neuro Oncol 2007 1.38
65 Bevacizumab plus irinotecan in recurrent WHO grade 3 malignant gliomas. Clin Cancer Res 2008 1.35
66 SB-431542, a small molecule transforming growth factor-beta-receptor antagonist, inhibits human glioma cell line proliferation and motility. Mol Cancer Ther 2004 1.35
67 TERT promoter mutations are highly recurrent in SHH subgroup medulloblastoma. Acta Neuropathol 2013 1.35
68 Resistance to tyrosine kinase inhibition by mutant epidermal growth factor receptor variant III contributes to the neoplastic phenotype of glioblastoma multiforme. Clin Cancer Res 2004 1.33
69 Phase II trial of murine (131)I-labeled antitenascin monoclonal antibody 81C6 administered into surgically created resection cavities of patients with newly diagnosed malignant gliomas. J Clin Oncol 2002 1.32
70 Overall survival of newly diagnosed glioblastoma patients receiving carmustine wafers followed by radiation and concurrent temozolomide plus rotational multiagent chemotherapy. Cancer 2009 1.29
71 Brain tumors in mice are susceptible to blockade of epidermal growth factor receptor (EGFR) with the oral, specific, EGFR-tyrosine kinase inhibitor ZD1839 (iressa). Clin Cancer Res 2002 1.27
72 Development of a real-time RT-PCR assay for detecting EGFRvIII in glioblastoma samples. Clin Cancer Res 2008 1.25
73 Targeted alpha-particle radiotherapy with 211At-labeled monoclonal antibodies. Nucl Med Biol 2007 1.25
74 Poliovirus receptor CD155-targeted oncolysis of glioma. Neuro Oncol 2004 1.23
75 Dendritic cells pulsed with a tumor-specific peptide induce long-lasting immunity and are effective against murine intracerebral melanoma. Neurosurgery 2002 1.23
76 Poly(ADP-ribose) polymerase-1 inhibition reverses temozolomide resistance in a DNA mismatch repair-deficient malignant glioma xenograft. Mol Cancer Ther 2005 1.23
77 A monoclonal antibody IMab-1 specifically recognizes IDH1R132H, the most common glioma-derived mutation. Biochem Biophys Res Commun 2009 1.22
78 Glioblastoma Multiforme Oncogenomics and Signaling Pathways. Clin Med Oncol 2009 1.21
79 Detection of humoral response in patients with glioblastoma receiving EGFRvIII-KLH vaccines. J Immunol Methods 2008 1.19
80 A review of VEGF/VEGFR-targeted therapeutics for recurrent glioblastoma. J Natl Compr Canc Netw 2011 1.16
81 ZD6474, a novel tyrosine kinase inhibitor of vascular endothelial growth factor receptor and epidermal growth factor receptor, inhibits tumor growth of multiple nervous system tumors. Clin Cancer Res 2005 1.16
82 Global identification of MLL2-targeted loci reveals MLL2's role in diverse signaling pathways. Proc Natl Acad Sci U S A 2012 1.14
83 Quantitative analysis of O6-alkylguanine-DNA alkyltransferase in malignant glioma. Mol Cancer Ther 2006 1.13
84 Salvage radioimmunotherapy with murine iodine-131-labeled antitenascin monoclonal antibody 81C6 for patients with recurrent primary and metastatic malignant brain tumors: phase II study results. J Clin Oncol 2006 1.12
85 The heat shock response and chaperones/heat shock proteins in brain tumors: surface expression, release, and possible immune consequences. J Neurosci 2007 1.11
86 Mismatch repair deficiency does not mediate clinical resistance to temozolomide in malignant glioma. Clin Cancer Res 2008 1.10
87 Loss of phosphatase and tensin homologue increases transforming growth factor beta-mediated invasion with enhanced SMAD3 transcriptional activity. Cancer Res 2005 1.10
88 The genetic landscape of anaplastic astrocytoma. Oncotarget 2014 1.09
89 IDH1(R132) mutation identified in one human melanoma metastasis, but not correlated with metastases to the brain. Biochem Biophys Res Commun 2010 1.08
90 Colocalization of gadolinium-diethylene triamine pentaacetic acid with high-molecular-weight molecules after intracerebral convection-enhanced delivery in humans. Neurosurgery 2011 1.08
91 Evaluation of anti-podoplanin rat monoclonal antibody NZ-1 for targeting malignant gliomas. Nucl Med Biol 2010 1.08
92 Dosimetry and radiographic analysis of 131I-labeled anti-tenascin 81C6 murine monoclonal antibody in newly diagnosed patients with malignant gliomas: a phase II study. J Nucl Med 2005 1.08
93 A pilot study of IL-2Rα blockade during lymphopenia depletes regulatory T-cells and correlates with enhanced immunity in patients with glioblastoma. PLoS One 2012 1.08
94 Construction of an immunotoxin, D2C7-(scdsFv)-PE38KDEL, targeting EGFRwt and EGFRvIII for brain tumor therapy. Clin Cancer Res 2013 1.07
95 Myeloablative temozolomide enhances CD8⁺ T-cell responses to vaccine and is required for efficacy against brain tumors in mice. PLoS One 2013 1.07
96 Effect of CYP3A-inducing anti-epileptics on sorafenib exposure: results of a phase II study of sorafenib plus daily temozolomide in adults with recurrent glioblastoma. J Neurooncol 2010 1.06
97 KMT2D maintains neoplastic cell proliferation and global histone H3 lysine 4 monomethylation. Oncotarget 2013 1.06
98 Aptamers selected against the unglycosylated EGFRvIII ectodomain and delivered intracellularly reduce membrane-bound EGFRvIII and induce apoptosis. Biol Chem 2009 1.05
99 Oncolytic polio virotherapy of cancer. Cancer 2014 1.05
100 Secreted protein acidic, rich in cysteine (SPARC), mediates cellular survival of gliomas through AKT activation. J Biol Chem 2004 1.04
101 O6-benzylguanine-mediated enhancement of chemotherapy. Mol Cancer Ther 2002 1.04
102 Mutant IDH1 is required for IDH1 mutated tumor cell growth. Oncotarget 2012 1.03
103 Reversing the Warburg effect as a treatment for glioblastoma. J Biol Chem 2013 1.02
104 miR-33a promotes glioma-initiating cell self-renewal via PKA and NOTCH pathways. J Clin Invest 2014 1.02
105 Recombinant anti-podoplanin (NZ-1) immunotoxin for the treatment of malignant brain tumors. Int J Cancer 2012 1.01
106 Glioblastoma multiforme and the epidermal growth factor receptor. N Engl J Med 2005 1.00
107 Radioimmunotargeting of malignant glioma by monoclonal antibody D2C7 reactive against both wild-type and variant III mutant epidermal growth factor receptors. Nucl Med Biol 2011 0.99
108 Association between glioma and history of allergies, asthma, and eczema: a case-control study with three groups of controls. Cancer Epidemiol Biomarkers Prev 2009 0.99
109 A pilot study: 131I-antitenascin monoclonal antibody 81c6 to deliver a 44-Gy resection cavity boost. Neuro Oncol 2008 0.99
110 Exercise interest and preferences among patients diagnosed with primary brain cancer. Support Care Cancer 2006 0.99
111 The combination of novel low molecular weight inhibitors of RAF (LBT613) and target of rapamycin (RAD001) decreases glioma proliferation and invasion. Mol Cancer Ther 2007 0.98
112 Sustained radiographic and clinical response in patient with bifrontal recurrent glioblastoma multiforme with intracerebral infusion of the recombinant targeted toxin TP-38: case study. Neuro Oncol 2005 0.98
113 A novel method for volumetric MRI response assessment of enhancing brain tumors. PLoS One 2011 0.98
114 Monitoring radiographic brain tumor progression. Toxins (Basel) 2011 0.98
115 Antibody, T-cell and dendritic cell immunotherapy for malignant brain tumors. Future Oncol 2013 0.97
116 Antitenascin-C monoclonal antibody radioimmunotherapy for malignant glioma patients. Expert Rev Anticancer Ther 2007 0.97
117 EGFR phosphorylation of DCBLD2 recruits TRAF6 and stimulates AKT-promoted tumorigenesis. J Clin Invest 2014 0.97
118 Chaperone proteins and brain tumors: potential targets and possible therapeutics. Neuro Oncol 2005 0.97
119 Assessment of type of allergy and antihistamine use in the development of glioma. Cancer Epidemiol Biomarkers Prev 2011 0.96
120 Consistency of primary brain tumor diagnoses and codes in cancer surveillance systems. Neuroepidemiology 2004 0.96
121 The history, evolution, and clinical use of dendritic cell-based immunization strategies in the therapy of brain tumors. J Neurooncol 2003 0.96
122 MRP3: a molecular target for human glioblastoma multiforme immunotherapy. BMC Cancer 2010 0.96
123 N-succinimidyl 3-[211At]astato-4-guanidinomethylbenzoate: an acylation agent for labeling internalizing antibodies with alpha-particle emitting 211At. Nucl Med Biol 2003 0.95
124 AAL881, a novel small molecule inhibitor of RAF and vascular endothelial growth factor receptor activities, blocks the growth of malignant glioma. Cancer Res 2006 0.95
125 Chemotherapy and novel therapeutic approaches in malignant glioma. Front Biosci 2005 0.95
126 Mibefradil, a novel therapy for glioblastoma multiforme: cell cycle synchronization and interlaced therapy in a murine model. J Neurooncol 2012 0.94
127 GNOSIS: guidelines for neuro-oncology: standards for investigational studies-reporting of phase 1 and phase 2 clinical trials. Neuro Oncol 2005 0.93
128 Molecular markers of prognosis in astrocytic tumors. Cancer 2002 0.93
129 Improved xenograft targeting of tumor-specific anti-epidermal growth factor receptor variant III antibody labeled using N-succinimidyl 4-guanidinomethyl-3-iodobenzoate. Nucl Med Biol 2002 0.92
130 Malignant brainstem gliomas in adults: clinicopathological characteristics and prognostic factors. J Neurooncol 2014 0.92
131 BLyS levels correlate with vaccine-induced antibody titers in patients with glioblastoma lymphodepleted by therapeutic temozolomide. Cancer Immunol Immunother 2013 0.92
132 EGFRvIII-targeted immunotoxin induces antitumor immunity that is inhibited in the absence of CD4+ and CD8+ T cells. Cancer Immunol Immunother 2007 0.92
133 Survival analysis of presumptive prognostic markers among oligodendrogliomas. Cancer 2005 0.92
134 A sphingosine kinase inhibitor induces cell death in temozolomide resistant glioblastoma cells. Cancer Chemother Pharmacol 2009 0.92
135 Mechanisms of resistance to 1,3-bis(2-chloroethyl)-1-nitrosourea in human medulloblastoma and rhabdomyosarcoma. Mol Cancer Ther 2002 0.92
136 Phase 2 trial of BCNU plus irinotecan in adults with malignant glioma. Neuro Oncol 2004 0.91
137 Toxin-based targeted therapy for malignant brain tumors. Clin Dev Immunol 2012 0.91
138 Treatment of HER2-positive breast carcinomatous meningitis with intrathecal administration of alpha-particle-emitting (211)At-labeled trastuzumab. Nucl Med Biol 2009 0.91
139 Using the theory of planned behavior to understand the determinants of exercise intention in patients diagnosed with primary brain cancer. Psychooncology 2007 0.90
140 Brain tumor cell lines resistant to O6-benzylguanine/1,3-bis(2-chloroethyl)-1-nitrosourea chemotherapy have O6-alkylguanine-DNA alkyltransferase mutations. Mol Cancer Ther 2004 0.90
141 Affinity-matured anti-glycoprotein NMB recombinant immunotoxins targeting malignant gliomas and melanomas. Int J Cancer 2010 0.90
142 Imaging of convection enhanced delivery of toxins in humans. Toxins (Basel) 2011 0.90
143 HDMX regulates p53 activity and confers chemoresistance to 3-bis(2-chloroethyl)-1-nitrosourea. Neuro Oncol 2010 0.89
144 Convection enhanced delivery of macromolecules for brain tumors. Curr Drug Discov Technol 2012 0.89
145 Enzyme redesign guided by cancer-derived IDH1 mutations. Nat Chem Biol 2012 0.88
146 Cellular redox modulator, ortho Mn(III) meso-tetrakis(N-n-hexylpyridinium-2-yl)porphyrin, MnTnHex-2-PyP(5+) in the treatment of brain tumors. Anticancer Agents Med Chem 2011 0.87
147 A novel bispecific antibody recruits T cells to eradicate tumors in the "immunologically privileged" central nervous system. Oncoimmunology 2013 0.87
148 GMab-1, a high-affinity anti-3'-isoLM1/3',6'-isoLD1 IgG monoclonal antibody, raised in lacto-series ganglioside-defective knockout mice. Biochem Biophys Res Commun 2009 0.87
149 Glioblastoma proto-oncogene SEC61gamma is required for tumor cell survival and response to endoplasmic reticulum stress. Cancer Res 2009 0.87
150 Heat shock protein 70-binding protein 1 is highly expressed in high-grade gliomas, interacts with multiple heat shock protein 70 family members, and specifically binds brain tumor cell surfaces. Cancer Sci 2009 0.87
151 Phase I trial of temozolomide plus O6-benzylguanine 5-day regimen with recurrent malignant glioma. Neuro Oncol 2009 0.87
152 Phase II trial of Gliadel plus O6-benzylguanine in adults with recurrent glioblastoma multiforme. Clin Cancer Res 2009 0.87
153 Recombinant single-chain variable fragment antibodies against extracellular epitopes of human multidrug resistance protein MRP3 for targeting malignant gliomas. Int J Cancer 2010 0.87
154 Comprehensive molecular cytogenetic investigation of chromosomal abnormalities in human medulloblastoma cell lines and xenograft. Neuro Oncol 2002 0.87
155 Phase 1 trial of irinotecan plus BCNU in patients with progressive or recurrent malignant glioma. Neuro Oncol 2004 0.86
156 Mechanism of anti-glioma activity and in vivo efficacy of the cannabinoid ligand KM-233. J Neurooncol 2012 0.85
157 Phase II study of Cloretazine for the treatment of adults with recurrent glioblastoma multiforme. Neuro Oncol 2006 0.85
158 Decoupling of DNA damage response signaling from DNA damages underlies temozolomide resistance in glioblastoma cells. J Biomed Res 2010 0.84
159 An EGFRvIII-targeted bispecific T-cell engager overcomes limitations of the standard of care for glioblastoma. Expert Rev Clin Pharmacol 2013 0.84
160 Monoclonal antibodies for brain tumour treatment. Expert Opin Biol Ther 2004 0.84
161 Anti-EGFRvIII monoclonal antibody armed with 177Lu: in vivo comparison of macrocyclic and acyclic ligands. Nucl Med Biol 2010 0.83
162 Comparative genomic hybridization analysis of astrocytomas: prognostic and diagnostic implications. J Mol Diagn 2004 0.83
163 Activity of VNP40101M (Cloretazine) in the treatment of CNS tumor xenografts in athymic mice. Neuro Oncol 2007 0.83
164 Rational design and generation of recombinant control reagents for bispecific antibodies through CDR mutagenesis. J Immunol Methods 2013 0.83
165 Aberrant Otx2 expression enhances migration and induces ectopic proliferation of hindbrain neuronal progenitor cells. PLoS One 2012 0.83
166 IDH1 and IDH2 hotspot mutations are not found in canine glioma. Int J Cancer 2010 0.83
167 Central nervous system. Cancer Biomark 2010 0.82
168 Induction of the unfolded protein response drives enhanced metabolism and chemoresistance in glioma cells. PLoS One 2013 0.82
169 Phase 1 trial study of 131I-labeled chimeric 81C6 monoclonal antibody for the treatment of patients with non-Hodgkin lymphoma. Blood 2004 0.82
170 Evaluation of an internalizing monoclonal antibody labeled using N-succinimidyl 3-[131I]iodo-4-phosphonomethylbenzoate ([131I]SIPMB), a negatively charged substituent bearing acylation agent. Nucl Med Biol 2004 0.82
171 Novel human IgG2b/murine chimeric antitenascin monoclonal antibody construct radiolabeled with 131I and administered into the surgically created resection cavity of patients with malignant glioma: phase I trial results. J Nucl Med 2006 0.82
172 Antitenascin antibody 81C6 armed with 177Lu: in vivo comparison of macrocyclic and acyclic ligands. Nucl Med Biol 2007 0.82
173 Utility of EGFR and PTEN numerical aberrations in the evaluation of diffusely infiltrating astrocytomas. Laboratory investigation. J Neurosurg 2008 0.81
174 Affinity-matured recombinant immunotoxin targeting gangliosides 3'-isoLM1 and 3',6'-isoLD1 on malignant gliomas. MAbs 2013 0.81
175 Multiple phenotypic changes in mice after knockout of the B3gnt5 gene, encoding Lc3 synthase--a key enzyme in lacto-neolacto ganglioside synthesis. BMC Dev Biol 2010 0.80
176 Proteomic profiling of patient-derived glioblastoma xenografts identifies a subset with activated EGFR: implications for drug development. J Neurochem 2015 0.80
177 Isocitrate dehydrogenase 1: what it means to the neurosurgeon: a review. J Neurosurg 2013 0.79
178 Antiepidermal growth factor variant III scFv fragment: effect of radioiodination method on tumor targeting and normal tissue clearance. Nucl Med Biol 2006 0.78
179 Tumor resection cavity administered iodine-131-labeled antitenascin 81C6 radioimmunotherapy in patients with malignant glioma: neuropathology aspects. Nucl Med Biol 2007 0.78
180 Tenascin and microvessel stromal changes in patients with non-Hodgkin's lymphoma are isolated to the sites of disease and vary in correlation to disease activity. Leuk Lymphoma 2005 0.78
181 Human exposure to selected animal neurocarcinogens: a biomarker-based assessment and implications for brain tumor epidemiology. J Toxicol Environ Health B Crit Rev 2009 0.78
182 Immunotherapy of brain tumors. Handb Clin Neurol 2012 0.78
183 Therapeutic aspects of chaperones/heat-shock proteins in neuro-oncology. Expert Rev Anticancer Ther 2006 0.77
184 BCNU-sequestration by metallothioneins may contribute to resistance in a medulloblastoma cell line. Cancer Chemother Pharmacol 2008 0.77
185 Immunotherapy against angiogenesis-associated targets: evidence and implications for the treatment of malignant glioma. Expert Rev Anticancer Ther 2008 0.76
186 Generation of anti-idiotypic reagents in the EGFRvIII tumor-associated antigen system. Cancer Immunol Immunother 2001 0.76
187 Detection of amino-terminal extracellular domain of somatostatin receptor 2 by specific monoclonal antibodies and quantification of receptor density in medulloblastoma. Hybridoma (Larchmt) 2009 0.76
188 O (4)-benzylfolic acid inactivates O (6)-alkylguanine-DNA alkyltransferase in brain tumor cell lines. Cancer Chemother Pharmacol 2007 0.75
189 Validation of an Immunohistochemistry Assay for Detection of CD155, the Poliovirus Receptor, in Malignant Gliomas. Arch Pathol Lab Med 2017 0.75